Clinical Trial Update: A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating subcutaneous AZD9550 and AZD6234, alone or in combination, against placebo in individuals with obesity/overweight; sponsored by Astra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• AZD6234
• AZD9550

Snippet

Sponsor: AstraZeneca | Conditions: Obesity or Overweight | Phase 2 | Status: ACTIVE_NOT_RECRUITING